UT Physicians Rheumatology Clinic
Rheumatology
Dr. Filemon K. Tan, MD
|
|
Give Review
Doctor Filemon K. Tan, MD practices Rheumatology. He graduated from University of Texas Medical School. He received 3 awards: "Top Doctors:SE Texas", "Super Doctor" and "Fellow (FACR)". Filemon is also a published MD. He has 59 publication published. The most recent publication is: Identification of an Association of TNFAIP3 Polymorphisms With Matrix Metalloproteinase Expression in Fibroblasts in an Integrative Study of Systemic Sclerosis-Associa... Filemon is registered with Medicare.
Publications
- Identification of an Association of TNFAIP3 Polymorphisms With Matrix Metalloproteinase Expression in Fibroblasts in an Integrative Study of Systemic Sclerosis-Associa...
- Unique Temporal and Spatial Expression Patterns of IL-33 in Ovaries during Ovulation and Estrous Cycle Are Associated with Ovarian Tissue Homeostasis.
- Identification of cadherin 11 as a mediator of dermal fibrosis and possible role in systemic sclerosis.
- Secondary use of existing public microarray data to predict outcome for hepatoCellular carcinoma.
- Immunochip analysis identifies multiple susceptibility Loci for systemic sclerosis.
- Identification of cadherin-11 as a mediator of dermal fibrosis and possible role in systemic sclerosis.
- Skin gene expression correlates of severity of interstitial lung Disease in systemic sclerosis.
- Confirmation of TNIP1 but not RHOB and PSORS1C1 as systemic sclerosis risk factors in a large independent replication study.
- New insight on the Xq28 association with systemic sclerosis.
- Correlation of interferon-inducible chemokine plasma levels with Disease severity in systemic sclerosis.
- Nucleic acid-containing amyloid fibrils potently induce type I interferon and stimulate systemic autoimmunity.
- Osteopontin in systemic sclerosis and its role in dermal fibrosis.
- IRF5 polymorphism predicts prognosis in patients with systemic sclerosis.
- Decreased catalytic function with altered sumoylation of DNA topoisomerase I in the nuclei of scleroderma fibroblasts.
- Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts.
- Gene expression changes in multiple sclerosis relapse suggest activation of T and non-T Cells.
- HLA-B35 upregulates endothelin-1 and downregulates endothelial nitric oxide synthase via endoplasmic reticulum stress response in endothelial Cells.
- Separate influences of birth order and gravidity/parity on the development of systemic sclerosis.
- Systemic sclerosis and Lupus: points in an interferon-mediated continuum.
- Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines.
- Genetics and genomic studies in scleroderma (systemic sclerosis).
- Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors.
- Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis.
- Attenuation of collagen production with small interfering RNA of SPARC in cultured fibroblasts from the skin of patients with scleroderma.
- Induction of apoptosis and fibrillin 1 expression in human dermal endothelial Cells by scleroderma sera containing anti-endothelial Cell antibodies.
- Autoantibodies against PDGF receptor in scleroderma.
- Gene profiling of scleroderma skin reveals robust signatures of Disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts.
- Systemic lupus erythematosus in a multiethnic US cohort: XXXVI. Influence of mannose-binding lectin exon 1 polymorphisms in Disease manifestations, course, and outcome.
- Genetics of scleroderma: update on single nucleotide polymorphism analysis and microarrays.
- Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-beta pathway to recapitulate the "scleroderma phenotype".
- Monozygotic twins clinically Discordant for scleroderma show concordance for fibroblast gene expression profiles.
- Polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in systemic sclerosis.
- Classification analysis of the transcriptosome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early Disease.
- Small interfering RNA inhibition of SPARC attenuates the profibrotic effect of transforming growth factor beta1 in cultured normal human fibroblasts.
- Genetic signatures of pre-expansion bottleNeck in the Choctaw population of Oklahoma.
- Fibrillin 1 abnormalities in dermal fibroblast cultures from first-degree relatives of patients with systemic sclerosis (scleroderma).
- Identification of novel targets in scleroderma: update on population studies, cDNA arrays, SNP analysis, and mutations.
- Examination of the possible role of biologically relevant genes around FBN1 in systemic sclerosis in the Choctaw population.
- Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high Disease prevalence.
- Systemic sclerosis: the susceptible host (genetics and environment).
- Association of novel polymorphisms with the expression of SPARC in normal fibroblasts and with susceptibility to scleroderma.
- Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue Diseases.
- The complex genetics of scleroderma.
- cDNA microarrays reveal distinct gene expression clusters in idiopathic inflammatory myopathies.
- Systemic Lupus erythematosus in a multiethnic US cohort: XXXIV. Deficient mannose-binding lectin exon 1 polymorphisms are associated with cerebrovascular but not with ...
- Association of interleukin 23 receptor polymorphisms with anti-topoisomerase-I positivity and pulmonary hypertension in systemic sclerosis.
- Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations.
- Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations.
- Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis.
- Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Cauc...
- Association of 5''-untranslated region of the Fibrillin-1 gene with Japanese scleroderma.
- Genotypic analysis of the TGF beta-509 allele in patients with systemic lupus erythematosus and Sjogren''s Syndrome.
- Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus.
- TGFBR2 mutations alter smooth muscle Cell phenotype and predispose to thoracic aortic aneurysms and dissections.
- Whole-blood gene expression profiling in Ankylosing spondylitis shows upregulation of toll-like receptor 4 and 5.
- Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy.
- A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations.
- Novel identification of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis.
Schools
University Of Texas Medical School At Houston
University Tex Med School
Procedures Preformed
- Joint Drainage
- Myofascial Trigger Point Injection
- Steroid Injection
- Trigger Point Injection
Conditions Treated
- Achilles Tendinitis
- Amyloidosis
- Ankylosing Spondylitis
- Arthritis
- View All
Doctors Specialties
- Rheumatology
Accepted Insurances
Awards
- Top Doctors:SE Texas
- Super Doctor
- Fellow (FACR)
Education
-
University of Texas Health Science Center -
University of Texas Medical School
Drug Facts
| NPI NUMBER | 1083632319 | |
| NPPES Provider LastName | TAN | |
| NPPES Provider FirstName | FILEMON | |
| NPPES Provider ZIPCode | 770303000 | |
| NPPES Provider State | TX | |
| Specialty Description | Rheumatology | |
| Total Claim Count | 1021.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 44.0 | |
| Percent Opioid Claims | 4.31 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1083632319 |
| Last Name Of The Provider | TAN |
| First Name Of The Provider | FILEMON |
| View All |
Similar Doctors
|
Dr. Holly J. Jones, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sreekanth Chintamaneni, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David P. Huston, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Oluyemisi O. Awobokun, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Prateek Chaudhary, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Javier P. Berrios, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gwendoline N. Menga, DO
This Doctor is OpenDoctor Recommended.
|
|
Dr. Qaiser Rehman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joan Appleyard, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gineth P. Pinto-Patarroyo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jacqueline Vo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary C. Gibson, MD |
|
|
Dr. Gloria C. Salazar, MD |